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Abstract Over the last decade, the increasingly significant
problem of osteoporosis in men has begun to receive much
more attention than in the past. In particular, recent observa-
tions from large scale population studies in males led to an
advance in the understanding of morphologic basis of growth,
maintenance and loss of bone in men, as well as new insights
about the pathophysiology and treatment of this disorder.
While fracture risk consistently increases after age 65 in men
(with up to 50 % of cases due to secondary etiologies), osteo-
porosis and fractures may also occur in young or middle aged
males in the absence of an identifiable etiology. For this cate-
gory (so called idiopathic osteoporosis), there are still major
gaps in knowledge, particularly concerning the etiology and the
clinical management. This article provides a summary of recent
developments in the acquisition and maintenance of bone
strength in men, as well as new insights about the pathogenesis,
diagnosis, and treatment of idiopathic osteoporosis.
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Introduction
While osteoporosis has been traditionally considered to be a
disease of aging women, it is becoming an increasingly im-
portant health problem in men. The increased longevity of the
population is in part responsible for this observation but
enhanced awareness of this problem in men is also notewor-
thy. Different population-based studies clearly demonstrate
that aging in men, similar to aging in women, is associated
with dramatic increases in fracture risk [1, 2]. It has been
estimated that the lifetime risk of a man suffering an osteopo-
rotic fracture is actually greater than his likelihood of devel-
oping prostate cancer [3].
As in women, osteoporosis in men could be due to second-
ary etiologies requiring careful clinical evaluation (Table 1) [2,
4–7]. The 3 major secondary causes of osteoporosis in men
(accounting for up to 40 % of all men with osteoporosis) are
alcohol abuse, glucocorticoid excess (most commonly, chron-
ic glucocorticoid therapy and rarely Cushing’s syndrome), and
hypogonadism [4, 5]. Other important etiologies to rule out
include excessive thyroid hormone exposure (either hyperthy-
roidism or overtreatment with thyroid hormone), gas-
trointestinal disorders (particularly celiac disease), chronic
obstructive pulmonary disease, neuromuscular disorders, mul-
tiple myeloma or other malignancies, hyperparathyroidism,
rheumatic disorders (eg, rheumatoid arthritis), diabetes
mellitus, renal insufficiency, HIV infection, and other drugs
(anticonvulsants, high-dose chemotherapeutics, selective se-
rotonin reuptake inhibitors) [2, 4–7]. Overall, the prevalence
of these secondary causes of osteoporosis is higher in men
than in women, exceeding 50% inmany series. In the absence
of an identifiable etiology, male osteoporosis is referred to as
“idiopathic osteoporosis,” particularly in individuals less than
65–70 years of age. Of course, there are men over 70 with
bone fragility whose cause is not known. The older the patient,
however, the more likely attribution of cause will be related to
age-related bone loss and not to a specific or unknown condi-
tion. Moreover, as in women, other factors, such as smoking,
physical inactivity, excessive leanness, and chronically low
calcium intake may accelerate age-related bone loss or other
etiologic cause in men [5].
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This article reviews what is known about the factors in men
that lead to acquisition, maintenance and loss of bone, as well
as new insights about the pathogenesis, diagnosis, and treat-
ment of idiopathic osteoporosis in men.
Epidemiology
Prevalence of Fractures
The lifetime risk of any clinical osteoporotic fracture of the
hip, vertebrae, or wrist in white men is 13 % compared with
40 % in women [8]. It has been estimated that worldwide in
the year 2000 about 30% of hip, 20% of forearm, and 42% of
clinical vertebral fractures occurred in men [1]. These figures
are likely to vary according to the country studied. For exam-
ple, in Australia 1 in 3 men over 60 will suffer a fracture due to
osteoporosis [9]. Moreover, a 0.3 % increase in the 10-year
probability of hip fracture has been described in men for each
10° increment in latitude, thus, supporting a protective role of
sunlight exposure, or other latitude-dependent effect, on hip
fracture risk [10]. Differences in ethnicity are also relevant,
with lower fractures rates described in African and African
American men than Caucasian men [11].
As in women, the absolute risk of a subsequent fracture in
men increases substantially after the first fracture [12]. From the
Australian Dubbo Osteoporosis Study Cohort of community-
dwelling men aged 60 years or older, the relative risk of
subsequent fractures following a low-trauma fracture was
higher in men (relative risk [RR] 3.47; 95 % confidence
intervals [CI] 2.68–4.48) than in women (RR 1.95; 95 % CI
1.70–2.25) [12]. Importantly and consistent with other obser-
vations in the same cohort, higher mortality rates following all
osteoporotic fractures were also observed in more men than
women [13–15]. Regarding hip-fractures, a population-based
Canadian study showed that after the fracture, either in-hospital
mortality rates or 1-year mortality is higher in men than in
women (10.2 % vs 4.7 % and 30.8 % vs 37.5 %, respectively)
[16]. Moreover, men are less likely to return to independent
living than women 1 year after the hip fracture [17].
Generally in men more than in women, fracture incidence
follows a bimodal distribution with 2 major peaks [2, 6]. The
first peak occurs between 15 and 45 years and is relatedmainly
to traumatic fractures (ie, due to working activities, sports, or
traffic accidents) particularly affecting the long bones. In this
age range, not surprisingly, men are up to 3 times more likely
to sustain a fracture than women [2]. Even though traumatic
fractures are not considered as typical osteoporosis-related
fractures, the analysis of 2 large US prospective studies pro-
vided evidence that high-trauma fractures are associated with
low BMD and increased risk of subsequent fracture in older
adults of both genders [18]. Moreover, a more recent observa-
tion by Amin et al. [19•] demonstrated that in boys, the
occurrence of a distal forearm fracture during childhood is
associated with an increased risk of subsequent fragility frac-
tures at both major osteoporotic sites (RR 2.6; 95 % CI 2.1–
3.3) and remaining sites (RR 1.7; 95 % CI 1.3–2.0). The
second peak in fracture incidence occurs in older men and is
similar to that observed in women. The age-related peak in
fracture incidence, though, starts after age 70, about a decade
older that the age-related peak in women. Most fragility frac-
tures in men involve the hip, vertebrae, forearm, and humerus,
although fragility fractures at other sites may also occur.
Typical low-trauma fractures are also seen in younger men,
40 to 60 years old with idiopathic osteoporosis [20]. With
Table 1 Major causes of osteoporosis in men
Primary osteoporosis
• Idiopathic osteoporosis (<65–70 y)
With low bone turnover
With high bone turnover and hypercalciuria (less frequent)
• Age-related osteoporosis (>70 y)
Secondary osteoporosis
• Alcoholism a
• Endocrine disorders a
Hypogonadism
Cushing’s syndrome
Diabetes (type 1 and 2)
Hyperthyroidism
Hyperparathyroidism (primary or secondary)
• Gastrointestinal disorders a
Malabsorption Syndromes (ie, inflammatory bowel diseases,
gluten enteropathy)
Primary biliary cirrhosis
Post gastrectomy syndromes
• Chronic obstructive pulmonary disease
• Organ transplantation osteoporosis a
• Immobilization
• Neuromuscular disorders
• Systemic illnesses
Mastocytosis
Rheumatoid arthritis
Multiple myeloma
HIV disease a
Various other malignancies
• Medication/drug-related
Glucocorticoids a
Androgen deprivation therapy
Selective serotonin reuptake inhibitors
Anticonvulsants a
Chemotherapeutics
Thiazolidinediones a
Thyroid hormone (when used in excess) a
a These secondary causes of osteoporosis are more likely to present in
young men with osteoporosis
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greater longevity of men and the increasing growth of the
population, the number of men with hip fracture worldwide
is estimated to increase markedly in the years to come [21].
Prevalence of Osteoporosis Based on Bone Densitometry
Despite recent progresses in this field, the use of bone mineral
density (BMD) to determine the presence of osteoporosis and
assess fracture risk in men is not as well standardized as it is in
women. According to the WHO criteria, in women the diag-
nosis of osteoporosis is established when the BMD T-score is
−2.5 or less (ie, 2.5 standard deviations below average peak
BMD of young healthy women) [22]. Two different diagnostic
cut points for osteoporosis have been used in men, based either
on the young normal male or young female reference groups.
Prevalence rates differ consistently in relation to these cut-
points. For example, the prevalence of osteopenia and osteo-
porosis in men over age 50 from the third National Health and
Nutrition Survey (NHANES III) were 28 %–47 % and 3 %–
6 %, respectively, using male cut-points while it was lower,
15 %–33 % and 1 %–4 % , respectively, using female cut-
points [23]. Prevalence rates are highest for Non-Hispanic
whites, compared with Mexican-American and Non-Hispanic
black men. Despite the ongoing controversy over which nor-
mative database to use in men, it seems intuitively more
attractive to use sex-specific reference ranges. Certainly, if
one bases the argument on relative risk, the male reference
will be preferable. The increase in RR as a function of reduced
T-scores is similar for men and women. However, if one uses
absolute bone density in g/cm2 to determine fracture risk
fracture risk between men and women for a given absolute
bone density in g/cm2 is the same. Since fracture risk is a
function of absolute bone density, not changes relative to
baseline, support has been gained to use a universal female
database for men and women [2]. Whatever reference database
is to be used, it is clear that many more men who sustain a
fragility fracture have osteopenic T-scores than osteoporotic
ones [24]. This is similar to the work of Siris et al. who showed
the “osteopenic” women, perhaps by their sheer greater num-
bers, had a greater risk of fracture than “osteoporotic” women.
Pathophysiology
Patterns of Bone Growth and Bone Loss in Men
Major differences exist concerning bone accrual and bone loss
among men and women, which account for the lower fracture
incidence observed in men [25, 26•]. In both genders, bone
growth occurs gradually during childhood and accelerates
dramatically with puberty. However, men achieve 8 %–10 %
greater peak bone mass than women. This increase in bone
mass has been detected by convention dual energy X-ray
absorptiometry (DXA), a technology that measures areal
BMD (grams/cm2). Larger areal density confers a mechanical
advantage because forces are distributed more widely over a
surface. It is important to note, however, that true bone density
(that is a volumetric index, vBMD, expressed as g/cm3) at
peak bone age is very similar among the sexes. Thus, the
increase in peak BMD observed by DXA in males is related
to the development of larger bones because of greater perios-
teal apposition, a process likely to be dependent on the effect
of androgens at periosteal bone (a mechanism that becomes
operative at puberty and continues throughout life). Consistent
with this hypothesis, cross-sectional, and longitudinal studies
using peripheral quantitative computed tomography (pQCT)
showed up to 40 % larger bone area in young adult men than
women [27, 28]. Indeed, during pubertal growth, bone area
increases equally in both sexes at central sites but more so in
men at peripheral sites, consistent with the view that the degree
of periosteal apposition is likely to be site specific. Moreover,
more recent evidence from high-resolution pQCT (HRpQCT)
shows significant differences in trabecular and cortical bone
development at the ultradistal radius between girls and boys
during the pubertal growth spurt [29]. While trabecular param-
eters did not change significantly during puberty in girls,
trabecular bone volume fraction and thickness were increased
throughout puberty in boys, and these changes were driven
mainly by testosterone and IGF-1 levels. There were no dif-
ferences in cortical thickness or cortical vBMD between boys
and girls at the end of puberty. Periosteal and endosteal cir-
cumferences increased in both sexes but were higher in boys
than in girls.
Of interest, these pQCT studies also indicate that in both
genders, the decline in bone mass begins soon, around the third
decade at trabecular bone sites, and accelerates in women after
menopause. Therefore, in the middle aged man, bone loss
proceeds at slower rates, unless a disorder (ie, hypogonadism)
or therapeutic castration for a disease like prostate cancer
intervenes. Moreover, with aging, bone in men is character-
ized by trabecular thinning, due to reduced bone formation,
rather than increased resorption and trabecular perforation, a
characteristic of the postmenopausal woman [30–32]. With
thinning, and not loss, of bone trabeculae, bone strength in
the vertebral body is maintained to a greater extent than the
scenario in the postmenopausal woman. Conversely, cortical
bone loss occurs after midlife in both sexes, around 65–
70 years [28]. However, periosteal bone formation remains
greater in aging men than in postmenopausal women, further
contributing to lower fracture risk, which is particularly evi-
dent at cortical bone sites [25].
Pathogenesis of Idiopathic Osteoporosis in Men
Aging is the major determinant of osteoporosis and fracture
incidence in men either in the presence or in the absence of
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comorbidities and secondary causes [25]. However, there is a
subset of men with so-called idiopathic osteoporosis who pres-
ent with 1 or more fractures (generally symptomatic vertebral
fractures) and low BMD before the age of 65–70 years. Of
interest, a positive family history of osteoporosis has been often
described in men with idiopathic osteoporosis, suggesting a
major role of genetic factors [33, 34]. Indeed, twin and family
studies have shown a predominant genetic effect on peak bone
mineral mass acquisition rather than on age-related bone loss in
both genders [35]. As in women, male offspring of subjects
with osteoporosis show reduced bone mass well before age-
related bone loss [33], suggesting the expression of inherited
determinants of osteoporotic risk from an early age. Consistent
with this postulate, a previous study on male twin-pairs of
different ages revealed that intra-pair differences in radial bone
mass and width increased with age both in monozygotic and
dizygotic pairs [36]. Moreover, a more recent 3-generation
study in men demonstrated that sons of men with osteoporosis
have reduced bone size and reduced volumetric BMD, despite
normal markers of bone remodeling, further reinforcing the
view that in men the effect of genetics on bone is mainly
growth-related rather than age-related [37]. Following the dis-
covery of mutations in aromatase (CYP119A1), estrogen recep-
tor alpha (ESR1), and LRP5 genes in rare syndromes associat-
ed with the presence of osteoporosis and fractures in young
male individuals [33, 35], polymorphisms in the same genes
have been associated with osteoporotic risk in men and partic-
ularly in men with idiopathic osteoporosis [38–45]. However,
the overall contribution of these genetic variants on BMD
variation and fractures risk remains limited.
Although the category is clearly a heterogeneous one (with
many different clinical phenotypes having been described)
[46], most men with idiopathic osteoporosis present a rather
typical clinical and histomorphometric phenotype that differs
from age-related osteoporosis. In fact, they often show normal
or slightly increased bone resorption but decreased bone for-
mation, due likely to osteoblast dysfunction [47]. This hy-
pothesis has been supported by several histomorphometric
and in vitro studies [48–54]. In fact osteoblast cultures from
men with idiopathic osteoporosis showed a slower prolifera-
tion rate as well as a decreased functional activity with a
reduction in the expression of genes related to matrix forma-
tion, such as collagen type 1 and osteocalcin [48, 49]. This
was consistent with most of the evidence from bone biopsies
and HRpQCTanalysis of these patients, showing a decrease in
bone turnover, bone volume, osteoblast surface, osteoblast
number, cortical thickness, and cortical porosity [50–54].
The latter was more severely impaired in osteoporotic patients
with a vertebral fracture than in those without fractures [52,
55]. Despite this evidence that suggests osteoblast dysfunction
as a major pathogenetic mechanism; circulating levels of
sclerostin (an osteocyte product and major inhibitor of wnt/
beta-catenin system and osteoblast activity) were surprisingly
decreased rather than increased in a single report of 116 men
with idiopathic osteoporosis [56].
Most of the structural abnormalities in trabecular and cor-
tical bone of men with osteoporosis have been related to
alterations in the endocrine system and particularly to im-
paired IGF-1 and sex hormone action [2, 5, 6, 57] (Fig. 1).
Indeed, even though men do not undergo an equivalent of the
menopause, both estrogen and androgen levels, and particu-
larly their free bioavailable fractions, decline slowly but pro-
gressively after 50–60 years of age, apparently as a result of
complex alterations in reproductive physiology, lifestyle fac-
tors, or increases in the levels of sex hormone binding globulin
(SHBG) [58–60, 61, 62, 63]. Although direct androgen effects
in the adult male skeleton help prevent osteoporosis by stim-
ulation of periosteal cortical bone apposition and muscular
strength, there is ample direct and indirect evidence indicating
a major role for androgen aromatization into estrogens in the
regulation of bone homeostasis in adult men [64–66]. It has
been also suggested that threshold concentrations of estradiol
may be required to limit age-related bone loss and that up to
40 %–50 % of middle-aged or elderly men might fall below
that threshold [64, 66]. Subjects with estradiol levels below
that threshold (around 16 pg/mL) exhibit a marked increase in
fracture risk [67]. Interestingly, a population-based cross-
sectional study using HRpQCT further characterized the age
effects on bone microstructure in men as well as its relation-
ship with hormonal variables [57]. In young men (20–
39 years), the conversion of thick trabeculae into more nu-
merous, thinner trabeculae observed from young adult to mid-
life was most closely associated with declining IGF-1 levels.
Conversely, sex steroids, and particularly bioavailable estra-
diol, appeared as the major hormonal determinants of trabec-
ular microstructure in elderly men. However, reduced IGF-1
and estradiol levels have both been often described in different
series of men with idiopathic osteoporosis [68–75]. Variation
in either SHBG or IGFBPs levels were also reported, which
may reduce the amount of free available concentrations of sex
hormones and IGF-1 within the bone, respectively [75, 76]. In
most of these studies, these hormonal alterations were corre-
lated with the observed impairment of histomorphometric
parameters of bone formation. Moreover, a decrease in estro-
gen receptor alpha protein expression was described in osteo-
blast and osteocytes from middle-aged men with idiopathic
osteoporosis [77]. Thus, in men with idiopathic osteoporosis,
an impairment in either IGF-1 or estradiol action on bone (or
both) might occur well before the physiological age-related
decrease in endocrine function, thus, explaining the presence
of low bone mass and fractures at a younger age. To this end,
observations in men with idiopathic osteoporosis and their
first-degree relatives suggest that these estrogen-related pertur-
bations are at least in part genetically determined and occur
mainly during growth [37, 73]. In particular, Lapuevy et al.
showed, in a cross-sectional analysis of a large series of cases,
Curr Osteoporos Rep (2013) 11:286–298 289
that men with idiopathic osteoporosis, compared with age-
matched controls with normal bone mass, have lower weight,
truncal height, and upper/lower body segment ratio. In addi-
tion, they have lower trabecular and cortical vBMD (at the
radius and tibia) and smaller cortical areas and thickness due to
larger endosteal circumferences [73]. Higher serum SHBG and
lower total estradiol, free estradiol, and free testosterone levels,
without differences in total testosterone were also demonstrat-
ed.Moreover, a similar bone phenotypewas present in the sons
of these affected men with lower trabecular BMD and a thinner
cortex at the radius. These observations suggest a genetic
component related to inadequate skeletal maturation and ac-
quisition of peak bone mass in idiopathic osteoporosis which
is, at least in part, related to relative estrogen deficiency. This is
consistent with some evidence from genetic-association stud-
ies in the general population, which reported an association
between estrogen levels and polymorphic variation of the
aromatase gene in young men before the attainment of peak
bone mass [44, 78]. In addition, osteopenia and reduced corti-
cal thickness due to greater endocortical circumference have
been described in case reports of young men with aromatase
deficiency or loss-of-function mutations of the ESR1 gene [5,
34, 64, 65]. Similarly, the reduction in IGF-1 levels, which can
be often observed inmenwith idiopathic osteoporosis seems to
be associated with a particular allelic configuration of the
polymorphicmicrosatellite region of the IGF-1 gene composed
of variable cytosine-adenosine repeats 1 kb upstream from the
transcription start site. In fact, the frequency of homozygosity
for the allele in question, designated 192, in a group of men
with idiopathic osteoporosis was twice as high as that in a
number of control populations [79].
Other hormonal factors, such as vitamin D insufficiency
and increases in serum PTH levels, have been more strictly
associated with age-related bone loss and fracture risk in
elderly men rather than in men with idiopathic osteoporosis
[80, 81]. Finally, it should be noted that certain heterogeneity
also exists, since a subset of men with idiopathic osteoporosis
shows hypercalciuria together with normal or increased bone
turnover, thus, suggesting that different pathogenetic mecha-
nisms might be related to idiopathic bone fragility in middle-
aged men [4, 5].
Diagnosis
Since BMD measurement is not a routine test in men (even in
the presence of clear risk factors), clinical features such as
height loss, kyphosis, fracture, or symptomatic back pain are
the most characteristic initial clinical presentations of male
osteoporosis. About 40 %–50 % of men diagnosed with
osteoporosis will be shown, upon further evaluation, to have
a secondary cause of bone fragility. Thus, a detailed screening
for secondary causes should be mandatory in the presence of a
man with low BMD and/or a fragility fracture. Moreover, in
the setting of a fragility fracture, it is necessary to rule out the
possibility of a pathologic fracture due, for instance, to a
skeletal metastasis or multiple myeloma. After the exclusion
of secondary causes, the hypothesis of primary idiopathic or
age-related osteoporosis can be considered in subjects aged
below or above 65–70 years, respectively.
At present there is no universally validated strategy for
therapeutic decision making in men. Decisions regarding
treatment should be based on the absolute risk of fracture.
Even though the majority of fractures occur in men whose
BMD measurements are in the osteopenic rather than osteo-
porotic range, BMD actually remains a key factor in decision
Fig. 1 Major pathogenetic
mechanisms of idiopathic
osteoporosis in men
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making. Based on current recommendations, measurement of
bone mass by dual energy X-ray absorptiometry (DXA) is
generally recommended in men 70 years of age or older, in
younger subjects when major risk factors for osteoporosis are
evident or in subjects with a previous fragility fracture [7, 82].
The guidelines of The Endocrine Society and the International
Society of Clinical Densitometry [83, 84] both recommend the
male-specific reference range (−2.5 SD below average peak
bone mass for 25-to 30-year-old young men) as a diagnostic
threshold. In contrast, the International Osteoporosis
Foundation (IOF) recommends the female database for diag-
nosis and, thus, a T-score −2.5 SD below the peak bone mass
of young women, which corresponds to a T-score of approx-
imately −2.75 in the male database [85, 86]. The uncertainty
over which referent database to use is a result of a differing
opinion as to whether absolute fracture risk or relative fracture
risk should be used. Moreover in men younger than age 50, Z-
score should be used when reporting BMD results [83], and a
standard X-ray of the spine should be considered in case of low
BMD levels, particularly when height loss has been reported,
in order to assess the presence of asymptomatic vertebral
fractures. More recent evidence suggested that the use of
pQCT, HRpQCT, and finite element analysis (FEA) could
improve fracture prediction in men, allowing a better analysis
of bone microarchitecture and strength of trabecular and corti-
cal compartments than densitometry [87–90]. However, these
techniques require further validation in prospective studies and
are not currently available in clinical practice.
Even though higher levels of bone turnover markers have
been associated with greater bone loss in older men [91, 92], a
prospective analysis in men aged above 65 years from the
Osteoporotic Fractures in Men (MrOS) study did not reveal
evidence for an independent association with the risk of hip or
nonspine fracture after adjustment for hip BMD [92].
Likewise, the use of these markers for the follow-up of the
anti-osteoporotic treatment in men remains controversial and
requires more studies. Moreover, in the setting of primary
osteoporosis in young or middle-aged men, fractures general-
ly occur with a low bone turnover rate and the assessment of
bone markers could be indicated to detect a condition of low
bone formation rather than increased bone resorption. The
measurement of sex hormone levels and their free bioavailable
fractions is of limited clinical relevance in idiopathic osteopo-
rosis and their use should be restricted to exclude the presence
of secondary osteoporosis due to hypogonadism.
In order to improve diagnostic accuracy, specific risk-
assessment tools such as FRAX (a fracture assessment tool
from the WHO) incorporating major clinical risk factors
(height, weight, family history of hip fracture, glucocorticoid
use, rheumatoid arthritis, alcohol intake, smoking, secondary
causes of osteoporosis) with age and eventually hip BMD
have been developed for the prediction of fracture risk in
postmenopausal women and men 50 years of age or older
[93]. The use of this algorithm (with and without BMD)
provides a country-specific estimate of 10-year probability
of hip fracture and major osteoporotic fractures (clinical ver-
tebral, hip, forearm, or humerus). Based on cost-effectiveness
analysis, the NOF in the USA identified a 10-year fracture
probability equal or greater than 3 % and 20 %, respectively,
for hip and major osteoporotic fractures as being sufficient to
justify treatment [94]. However, these guidelines are not uni-
versally accepted and recent validation studies from Australia
and Canada reported that FRAX algorithm underestimates
fracture risk in men [95, 96]. Indeed, in the Australian study
the Garvan nomogram (which includes age, sex, number of
non-major-trauma fractures since age 50, number of falls in
last 12 months, and femoral BMD) was superior to FRAX in
identifying fracture patients [95], but it is not known whether
this is true for other populations. Conversely, a more recent
analysis of the MrOS cohort reported that FRAX risk calcu-
lator without BMD was well calibrated to hip fracture but
overestimated major osteoporotic fractures in elderly men
[97].
Treatment
Therapeutic approaches to osteoporosis in men are less well
defined than in women. Most of the pharmacologic agents that
are currently available for men with osteoporosis have been
previously tested and approved for women. The studies in men,
in general, have not had adequate numbers of patients to
ascertain a change in fracture incidence. Rather, other surrogate
endpoints such as increases in BMD and changes in bone
turnover markers have been used. On the whole, however, even
without hard fracture endpoints, it seems that the efficacy of
these drugs in men is similar to that in women [98, 99•]. While
this approach could be reasonable at this stage for the treatment
of secondary or age-related osteoporosis in men (conditions
which share at least in part similar pathogenetic mechanisms in
both genders), major uncertainty remains concerning the treat-
ment of idiopathic osteoporosis in men, which is mainly char-
acterized by a decrease rather than an increase in bone turnover
and, which might relate to abnormalities in bone accrual.
Preventive interventions in males are similar to the ap-
proach used for women, and apply to all men. They include
adequate calcium (1200–1500 mg/d) and vitamin D (400–
600 IU/d) intake, avoidance of smoking or excessive alcohol
consumption, weight-bearing exercise, and use of fall-
prevention programs. However, drug therapy should be initi-
ated in all men at high risk for fracture. Despite the current
limitations in defining men at higher fracture risk and the lack
of universally validated criteria the use of antiresorptive or
anabolic compounds should be indicated in the following
conditions: (a) the presence of a fragility fracture (clinical or
morphometric vertebral or hip or other major osteoporotic
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fractures); (b) presence of a T-score at the lumbar spine,
femoral neck and/or total hip that is<−2.5; (c) in the USA
for those who have a T-score between −1.0 and −2.5 but in
whom FRAX calculates a risk for any type of fragility fracture
in the next 10 years >20 %, and for hip fracture >3 %; and (d)
long term glucocorticoid therapy [83, 94].
Pharmacologic agents approved by the FDA and/or
European Medical Agency (EMA) for the treatment of both
primary and secondary osteoporosis in men include different
bisphosphonates (alendronate, risedronate, and zoledronic ac-
id), teriparatide and strontium ranelate (Table 2). Alternative
beneficial therapies in the presence of idiopathic osteoporosis
might also include the use of recombinant human growth
hormone, given that abnormalities in IGF-1 system have been
associated with the suppression of bone formation in most
patients [68–70, 76]. However, this hypothesis has been in-
vestigated in a single study in a limited sample (n =29) of men
with idiopathic osteoporosis [100].
Antiresorptive Compounds
Bisphosphonate therapy is the mainstay of therapy for male
osteoporosis. Alendronate and risedronate are oral amino
substituted bisphosphonates that have been shown to increase
BMD and to reduce bone turnover markers in men with oste-
oporosis [101–106]. The randomized placebo-controlled trials
for both compounds were not designed or powered to deter-
mine anti-fracture efficacy. Indeed, a meta-analysis evaluating
cumulative anti-fracture efficacy of randomized controlled trials
indicated that alendronate treatment efficiently reduces the risk
of vertebral fractures in men with low bone mass or fractures
(odds ratio 0.44; 95 % CI 0.23–0.83), but there was insufficient
evidence to prove a significant effect on non-vertebral fractures
[107]. Similarly, in an open label clinical trial daily treatment
with risedronate 5 mg for 2 years reduced the incidence of a
new vertebral fracture by 60% and of nonvertebral fractures by
47 % compared with placebo [106]. Consistent with this obser-
vation, risedronate has also been shown to be effective in the
treatment of bone loss and the prevention of hip fractures in
men >65 years of age who have sustained a cerebrovascular
accident [108]. More recently, consistent results with the use of
the most potent bisphosphonate, zoledronic acid (administered
intravenously at a dose of 5 mg once yearly), were observed in
osteoporotic men. This drug was as effective as alendronate in
increasing BMD and in reducing bone turnover markers in men
with idiopathic osteoporosis or osteoporosis due to
hypogonadism [109], while it was superior to risedronate in
increasing BMD and reducing bone turnover markers in the
treatment and prevention of glucocorticoid-induced osteoporo-
sis [110]. Moreover, in a post-hip-fracture trial performed in a
mixed male and female population, zoledronic acid lowered the
subsequent clinical fracture rate and decrease mortality com-
pared with placebo [111]. A subsequent gender specific analy-
sis of the same trial confirmed that the BMD increases were of a
similar magnitude in men to those observed in women [112].
However, the subset of males was too small to allow a gender
specific analysis on fracture and mortality. Of interest, a more
recent placebo-controlled trial was specifically designed to
determine a difference in fracture endpoints in men and was
performed in a sufficiently large sample of 1199 men, 50–
85 years old, with primary or hypogonadism-associated osteo-
porosis [113••]. Overall, patients treated with zoledronic acid
had a 67 % reduction in RR of one or more new morphometric
vertebral fractures and a 3.3 % risk reduction in absolute risk
Table 2 Overview of currently approved medications for osteoporosis in men
Medication Dosage Main efficacy outcomes Approved by Major adverse events
BMD Fractures FDA EMA
Alendronate c Oral : 10 mg/d or 70 mg/w + + + Gastric, esophageal irritation, musculoskeletal pain (rare)
Risedronate c Oral: 5 mg/d, 35 mg/w,
75 mg twice/m
+ + + Gastric, esophageal irritation, musculoskeletal pain (rare)
Zoledronic acid c Intravenously: 5 mg/y + + + + Flu-like symptoms (acute phase reaction), hypocalcemia,
Teriparatide Subcutaneously:
20 mcg/d for 2 y
+ + + Headache, dizziness, hypercalcemia, nausea, diarrhea
Denosumab c Subcutaneously:
60 mg/every 6 m
+ (+)a + (+)b Eczema, cellulitis, hypocalcemia (rare)
Strontium Ranelated Oral: 2 g/d + + Abdominal discomfort, severe skin eruption
(with eosinophilia systemic syndrome, rare),
thromboembolism
aAntifracture efficacy (vertebral fractures) restricted to a trial in men receiving androgen deprivation therapy for non-metastatic prostate cancer
b Approved for the treatment of men at high risk of fracture receiving androgen deprivation therapy for non-metastatic prostate cancer
c Rarely reported severe adverse events of osteonecrosis of the jaw and atypical femur fractures have been reported
d Recently, strontium ranelate has been associated with cardiovascular events such as myocardial infarction, based on a benefit-risk assessment analysis
of pooled data from randomized studies
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(4.9 % vs 1.6 %; P=0.0016) after 2 years in comparison to the
placebo group. Furthermore, the active treatment group expe-
rienced fewer moderate to severe vertebral fractures and less
height loss in comparison with placebo. Results were similar in
men with osteoporosis due to hypogonadism and in men with
normal testosterone levels. No difference was seen in serious
adverse events between the zoledronic acid and placebo groups.
Although the power of the study to detect a reduction in the risk
of nonvertebral fracture was modest, rates of nonvertebral
fracture were consistently lower with zoledronic acid than
placebo, and with similar point estimates to that reported in
larger studies involving women. Moreover, since a similar
efficacy was also observed concerning the effects of zoledronic
acid on BMD and bone turnover markers between this trial in
men and previous trials in postmenopausal women, this data
provided further support for the precept that antiresorptive
treatments are indeed effective in both genders.
A antiresorptive class, represented by Denosumab (a
monoclonal antibody against RANKL, the major activator of
osteoclast recruitment and activity) has been recently ap-
proved by the FDA and EMA to increase bone mass in men
at high risk for fracture receiving androgen deprivation ther-
apy for non-metastatic prostate cancer, following the positive
outcomes of a large randomized controlled trial [114]. Patients
who received denosumab had a decreased incidence of new
vertebral fractures at 36 months (relative risk, 0.38; 95 %
confidence interval, 0.19 to 0.78; P=0.006). Moreover, fol-
lowing the efficacy results in increasing BMD and suppress-
ing bone resorption reported by a recent 12 months placebo-
controlled, phase 3 study in men with low BMD [115], in
September, 2012 denosumab has received an indication in the
USA for men with osteoporosis at high risk for fracture.
Despite the positive results on BMD of testosterone supple-
mentation in eugonadal man with osteoporosis [116], evidence
for fracture efficacy is weak even in the presence of
hypogonadism [117]. Thus, the recent recommendations of
The Endocrine Society emphasize the use of bisphosphonates
or other approved therapies even for hypogonadal men [83].
Interestingly, in eugonadal osteoporotic men, the observed
increase in BMD and the reduction in bone turnover following
testosterone supplementation positively correlated with change
in estradiol, but not in testosterone levels, further indicating that
the skeletal effects of androgens in men are mainly due to their
conversion to estrogens [116]. These data also provide a ratio-
nale for the use of selective estrogen receptor modulators
(SERMs). However, available data with raloxifene in normal
men is restricted to bone turnover with variable results
depending on circulating estrogen concentrations (bone resorp-
tionmarkers were reduced if baseline estradiol levels were low)
[118, 119]. Conversely, in men receiving androgen deprivation
therapy for prostate cancer, treatment with either raloxifene
or toremifene prevented bone loss in comparison to placebo
[120, 121] and, in case of toremifene, also decreased vertebral
fracture risk by 50 % [122]. Despite this evidence, further
information is required and, thus, at this stage, the use of
SERMs for male osteoporosis is not recommended.
Drugs with Osteoanabolic Activity on Bone
The development of drugs with osteoanabolic action on bone
has extended our therapeutic options for osteoporosis in wom-
en as well as in men. These medications can stimulate bone
formation and in some instances theymay restore bone quality
and quantity to a greater extent that can be obtained with
inhibitors of bone resorption. To date, parathyroid hormone
and its 1–34 analog represent the only osteoanabolic agents
available in many countries (with a maximum overall duration
of 24 months) for the treatment of osteoporosis in both gen-
ders. The full length, nativemolecule (PTH 1–84) and its 1–34
fragment (Teriparatide which is the only anabolic compound
approved by the FDA) are administered as daily subcutaneous
injection. Evidence for therapeutic efficacy in male osteopo-
rosis with PTH analogs was obtained in at least 3 different
trials [122–124]. In the largest of these studies by Orwoll et al.
treatment with teriparatide for 11 months in a mixed sample of
men with idiopathic osteoporosis, age-related osteoporosis or
osteoporosis due to hypogonadism increased BMD to virtual-
ly the same extent as in women [124]. Consistent with the
anabolic activity of this agent, markers of bone formation
increased significantly during treatment. Moreover, response
to treatment was similar regardless of gonadal status, age,
baseline bone mineral density, and body mass index.
Importantly, one of these studies was specifically designed
to address the efficacy of treatment in middle-aged men with
idiopathic osteoporosis (age range 30–68 years, mean
50 years) of whom 78 % had sustained fractures [123].
These men were previously characterized from the clinical
point of view showing low bone turnover and markedly
reduced indexes of bone formation on histomorphometry
[69, 70]. After 18 months, active treatment with PTH1-34
was associated with substantial increases in lumbar spine
and hip BMD, as well as with increases in bone turnover
markers. However, while antifracture efficacy at vertebral
and nonvertebral sites has been demonstrated with PTH ana-
logs in postmenopausal women, all the trials in men were not
designed nor powered to detect differences in fracture inci-
dence. Some indication of decreased vertebral fracture inci-
dence in men was provided by a follow-up study of men with
previous teriparatide treatment [125], as well as in a clinical trial
for glucocorticoid-induced osteoporosis in which women and
men were included [126, 127]. Indeed, in the latter trial,
teriparatide treatment was superior to alendronate in
terms of increases in BMD and prevention of fractures.
Concurrent therapies with antiresorptive compounds
such as bisphosphonates are not recommended, since
little or no benefits were observed in combination trials
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with alendronate or risedronate, respectively [128, 129].
Conversely, sequential therapy with bisphosphonates has
been recently shown to maintain or further enhance
bone mass after PTH is stopped [130]. Moreover, in
individuals who have been treated previously with an
antiresorptive agent, the subsequent actions of PTH on
bone density may be delayed, but only transiently, if
bone turnover is markedly suppressed [130].
A monoclonal antibody against sclerostin (an osteocyte
product inhibiting wnt/beta-catenin pathway and bone for-
mation) has been developed and is currently being tested as
a new osteoanabolic compound. Although this drug is not
available yet, reports of a single-dose, placebo-controlled,
randomized study, which enrolled both men and women,
showed that bone formation markers increased markedly
along with a substantial reduction in bone resorption
markers [131].
Compounds with a Mechanism of Action That is Not Known
Additional studies in men have been performed with stron-
tium ranelate (2 g/day) given orally, a compound that demon-
strated vertebral and non-vertebral anti-fracture efficacy in
women with postmenopausal osteoporosis through an
uncoupling action on bone metabolism (with mild stimulation
of bone formation combined with a mild antiresorptive effect)
[132], even though its exact mechanisms of action in bone
remain unclear. In a preliminary comparative, open-label, 1-
year study male patients treated with strontium ranelate expe-
rienced a greater increase in BMD than those who took
alendronate, even though this increment was partly dependent
to the actual incorporation of the strontium element into the
bone crystal [133]. More recent results from a 2-year placebo-
controlled trial in older men with primary osteoporosis (mean
age 73 years) demonstrated greater increases in lumbar and
femoral BMD with strontium ranelate compared with placebo
[134]. Moreover, a significant increase in bone alkaline phos-
phatase (a marker of bone formation) was observed in patients
treated with strontium ranelate. Based on these results, the
EMA has extended the indication for this compound to in-
clude the treatment of osteoporosis in men at increased risk of
fracture. More recently, safety issues have surfaced with this
drug and it is now recommended only in situations of severe
osteoporosis [135].
Conclusions
The increasingly important problem of osteoporosis in men
has begun to receive much-needed attention. In particular,
over the last decade, large scale population studies in men
have led to advances in understanding bone fragility and its
treatment in men. These mainly include important new
knowledge about the morphologic basis of bone growth and
bone loss at trabecular and cortical sites, as well as in the
pathophysiology and the diagnosis of the disorder, especially
concerning age-related and secondary causes osteoporosis in
men. However, osteoporosis and fractures may also occur in
young or middle aged males in the absence of an identifiable
etiology. For this category (so called idiopathic osteoporosis)
there are still major gaps in knowledge, particularly concer-
ning the pathogenesis, diagnosis, prediction of fracture risk,
and clinical management. In fact, current diagnostic ap-
proaches either based on BMD or fracture algorithms (ie,
FRAX) are less validated in men than in women and can be
generally applied only in subjects aged 50 years or above.
Importantly, both clinical and experimental evidence suggests
that idiopathic osteoporosis in men has different microstruc-
tural abnormalities than age-related bone loss and is mainly
characterized by impaired osteoblast activity and reduced
bone formation. While most of the current treatment options
for the treatment of osteoporosis in men are based on
antiresorptive agents, which suppress bone turnover,
osteoanabolic agents (ie, PTH analogs or the monoclonal
antibody against sclerostin) or strontium ranelate, an agent
with an unknown mechanism, should be conceptually a more
attractive therapy for men with idiopathic osteoporosis and
impaired osteoblast activity. However, only few and small-
scale studies were specifically performed in men with idio-
pathic osteoporosis and despite the positive outcomes on
BMD, evidence for a true benefit on fracture risk is generally
considered to be weak [121]. It is also likely that at least in a
subset of these males bone fragility is growth-related and
mainly dependent on genetic mechanisms.
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